Home Blog Page 1694

Mabwell’s Novel Anti‑IL‑11 Monoclonal Antibody 9MW3811 Approved by NMPA to Initiate Phase II Clinical Trial in Pathological Scarring

By
Advertorial Desk
-

SHANGHAI, Nov. 11, 2025 /PRNewswire/ — Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its novel anti‑IL‑11 monoclonal antibody 9MW3811 has received approval from the China National Medical Products Administration (NMPA) to initiate a Phase II clinical trial for pathological scarring. 9MW3811 becomes the world’s first IL‑11‑targeting therapeutic to enter clinical stage for this indication.

Interleukin‑11 (IL‑11) is a cytokine that plays a critical role in chronic inflammation and fibrosis across multiple organs, including the lungs, skin, kidneys, and liver. 9MW3811 is a proprietary IL-11-targeting humanized monoclonal antibody developed by Mabwell, classified as a Category 1 therapeutic biologic with independent intellectual property rights. It is designed to bind IL‑11 with high affinity and effectively inhibit abnormal activation of the IL‑11/IL‑11Rα signaling pathway. This intervention helps block the pathological progression of fibrosis‑related diseases.

Key advantages of 9MW3811 include:

  1. Higher target affinity and stronger signaling blockade capability
  2. A long half‑life exceeding one month, making it suitable for chronic diseases requiring long‑term treatment

Preclinical studies have shown that 9MW3811 demonstrated significant efficacy in multiple models such as pulmonary fibrosis, and showed potential application value in fibrosis related diseases such as hypertrophic scar and abnormal endometrial bleeding. Especially in human derived keloid animal models, 9MW3811 can effectively alleviate the process of skin fibrosis and reduce the volume of existing scars. 9MW3811 has been approved to initiate clinical studies in China, US and Australia for indications including advanced malignant tumors and idiopathic pulmonary fibrosis (IPF), and has completed Phase I trials in healthy volunteers in Australia and China. The results demonstrate favorable safety and a half-life exceeding one month, placing it at a leading position globally for this target. The Phase II clinical trial of 9MW3811 for pathological scarring is planned to start at the end of 2025.

IL 11 is also closely related to the occurrence of aging related diseases (Nature, 2024). Mabwell has reached an exclusive license agreement with CALICO Life Sciences, a company under Alphabet focusing on innovative anti aging therapies, for 9MW3811. In addition to having broad application prospects in multi-organ fibrotic diseases including IPF, thyroid eye disease, skin fibrosis, renal fibrosis, hepatic fibrosis and cardiac fibrosis, 9MW3811 also has potential application prospects in aging-related diseases such as chronic conditions caused by cellular senescence, age-related frailty, and longevity.

About Pathological scarring

Pathological scarring, encompassing hypertrophic scars, keloids, and contracture scars, is notably driven by IL-11-mediated fibroblast-to-myofibroblast transdifferentiation via upregulation of extracellular matrix and α-smooth muscle actin (α-SMA), as demonstrated in the study “CD39 Fibroblasts Enhance Myofibroblast Activation by Promoting IL-11 Secretion in Hypertrophic Scars” in Journal of Investigative Dermatology (2022). Targeting IL-11 signaling effectively reduces α-SMA positive fibroblasts, halting scar progression. According to Frost & Sullivan data, there are approximately 25 million patients with pathological scars worldwide (about 7.4 million in China), with incidence rates continuing to rise. The number of Chinese patients is expected to exceed 10 million by 2030. Therefore, IL-11-targeted therapy holds significant clinical value and market potential.

About Mabwell

Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with capabilities spanning the entire pharmaceutical value chain. The company is committed to providing more effective and accessible therapies to meet global medical needs, with a focus on oncology and aging-related diseases. Mabwell’s mission is “Explore Life, Benefit Health” and its vision is “Innovation, from Ideas to Reality.” For more information, please visit www.mabwell.com/en.

Forward-Looking Statements

This press release contains forward-looking statements including, but not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those relating to the Company’s product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. “Forward-looking statements” are statements that are not historical facts and involve a number of risks and uncertainties, which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would,” and similar expressions and the negatives of those terms.

Forward-looking statements are based on the Company’s current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company’s control, including, but not limited to: environment; politic; economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties deteriorate, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results.

The Company cautions all the persons not to place undue reliance on any such forward-looking statements, which speaks only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions, figures and assumptions in this press release are applicable to this statement.

Newegg Announces Launch of Storefront on SHEIN’s U.S. Marketplace

By
Advertorial Desk
-

New Collaboration Offers Customers Stylish Technology Products Curated with Female Gamers in Mind

LOS ANGELES, Nov. 11, 2025 /PRNewswire/ — SHEIN, the global online fashion and lifestyle retailer, today announced a new partnership with Newegg, Inc. (NASDAQ: NEGG), a global e-commerce leader for technology products. The Newegg storefront on SHEIN’s U.S. site will feature more than 1,000 technology products curated for gamers who prioritize personal style when purchasing the latest technology products.

SHEIN’s Newegg storefront blends fashion and technology, offering customers new ways to express individuality through their devices, accessories, and home setups. From powerful gaming laptops and sleek ultrabooks to discreet earbuds and bold over-ear headphones, the assortment highlights how technology has become as much a style choice as a functional necessity. Newegg, known worldwide for its broad selection of PC components, lets customers build systems to match their style preferences, from case design to cooling systems.

“Technology is deeply personal – it’s how people work, play, and express themselves,” said Katie Lau, director of corporate marketing at Newegg. “This collaboration with SHEIN creates a unique opportunity to bridge fashion and technology, showing how everything from your gaming setup to your earbuds can become part of your personal identity.”

According to a 2025 study from Euromonitor International, women are central to the gaming industry, with 38% of online female consumers playing weekly and driving growth across games, content, and related lifestyle products. For SHEIN and Newegg, this shift represents a chance to meet rising demand and connect with a generation that embraces fashion, lifestyle, and technology.

“We’re excited to partner with Newegg to offer customers innovative products that reflect their passions and enhance their lifestyles,” said George Chang, general manager and head of SHEIN Marketplace U.S. “With growing customer demand, SHEIN is evolving into a go-to destination for lifestyle products, with a focus on accessibility and self-expression.”

SHEIN’s Newegg online storefront is now available and features a curated range of finished tech products. The selection will be updated seasonally, reflecting emerging trends and customer demand.

SHEIN Marketplace is committed to continuing to provide sellers with the tools, resources, and support needed to set them up for success and is onboarding new sellers to meet the needs of its growing customer base; more information for prospective sellers can be found here.

About Newegg

Newegg, Inc. (NASDAQ: NEGG), headquartered in City of Industry, Calif., is a leading global e-commerce company focused on technology, electronics, gaming, and lifestyle products. Founded in 2001, Newegg provides direct-to-consumer and B2B solutions across North America, Europe, Asia Pacific, Latin America, and the Middle East. For more information, visit www.newegg.com.

About SHEIN

SHEIN is a global online fashion and lifestyle retailer, offering SHEIN branded apparel and products from a global network of vendors, all at affordable prices. SHEIN remains committed to making the beauty of fashion accessible to all, promoting its industry-leading, on-demand production methodology, for a smarter, future-ready industry. To learn more about SHEIN, visit www.sheingroup.com.

From Bangkok to the World: Aura Bangkok Clinic Showcases International Standards in Aesthetic Care

By
Advertorial Desk
-

BANGKOK, Nov. 11, 2025 /PRNewswire/ — Aura Bangkok Clinic, a leader in Thailand’s medical aesthetic industry, is enhancing the country’s reputation as a top destination for Thai beauty medical tourism through its global expertise, award-winning services, and internationally recognized training programs. Attracting international patients seeking safe, natural, and cost-effective treatments, the company continues to set benchmarks in patient care, innovation, and safety.

Discover more at https://aurabangkokclinic.com/en/home/
Discover more at https://aurabangkokclinic.com/en/home/

Strongly Recognized as a Leader in Thailand Aesthetic Excellence

Aura Bangkok Clinic’s dedication to quality has been acknowledged with multiple prestigious awards:

  • No. 1 in Thailand for Botox – Platinum Award for Wrinkle Relaxer
  • No. 1 in Thailand for Fillers – Platinum Award for Skin Quality
  • Highest combined purchase volume of Allergan Botox and Juvederm Fillers in Thailand – Sapphire Award for Facial Aesthetics
  • Top 1 clinic for highest order of Restylane Filler and Sculptra – Galderma Chain Clinic Award 2024
  • No. 1 Clinic with the Highest Orders of Ultraformer Lifting Device in Southeast Asia – Acme of Achievement Award Southeast Asia 2024
  • 5-star ratings across all branches, with more than 20,000 reviews on Google Maps

International Training Standards Strengthen Innovative Aesthetic Services

In addition to delivering exceptional patient care, Aura Bangkok Clinic actively contributes to the advancement of global medical aesthetics. The company participated in the Galderma Glow On Training program by Galderma, a world-renowned pharmaceutical company specializing in dermatology and aesthetic science, including Botox and fillers. Through this training, Aura’s doctors gained advanced expertise in Restylane fillers—Vital Light and Vital—as well as Sculptra, while also enhancing their skills in facial analysis, treatment planning, and safety protocols.

Aura’s doctors are also trained directly by technical educators from Ulthera, Ultraformer, and Oligio company, ensuring precise and standardized use of lifting technologies. This comprehensive training guarantees that every treatment meets the highest standards of safety, consistency, and effectiveness.

Aura Bangkok Clinic’s distinctive approach focuses on skin tightening and rejuvenation without altering the facial structure, delivering subtle, natural-looking enhancements using advanced technology and techniques that align with both U.S. FDA and Thai FDA regulations. This approach strongly appeals to international patients, who increasingly value authenticity and confidence over dramatic transformations.

Committed to Deliver Consistent Quality Across All Branches

Emphasizing the importance of consistent quality across all clinic branches, “I believe that every patient must receive the same high standard of care, no matter which branch or doctor they visit. We carefully select and train our medical team to ensure this consistency, because quality and safety always come first,” said Dr. Jetbodin Prakoonsuksapan, Chief Executive Officer.

Underscoring strong patient trust, Aura Bangkok Clinic has achieved consistent 5-star ratings across all of its branches on Google Maps, with more than 20,000 reviews from satisfied patients. This exceptional volume of positive feedback reflects the company’s commitment to professionalism, attentive care, and medical expertise.

With a combination of award-winning treatments, comprehensive medical training, and a patient-centered approach, Aura Bangkok Clinic continues to elevate Thailand’s beauty reputation as a leading destination for global medical aesthetics tourism.

About Aura Bangkok Clinic

Founded in 2014, Aura Bangkok Clinic is a world-class beauty destination offering advanced medical technology and innovations that meet international standards. Our skilled medical team has experience with over 100,000 successful cases, specializing in non-invasive aesthetic treatments. We ensure the highest level of safety by using only genuine and verifiable medications. Our mission is to provide attentive care that enhances the beauty and confidence of all our clients, offering reasonable prices, trustworthy service, and visible results. For more information, please visit https://aurabangkokclinic.com/en/home/

Strategic Partnership Between Sanyou Bio and Yugong Bio to Accelerate Expansion in High-End Synthetic Enzyme Market

By
Advertorial Desk
-

SHANGHAI, Nov. 11, 2025 /PRNewswire/ — Sanyou Bio and Yugong Bio today announced the signing of a strategic cooperation agreement. This powerful alliance marks a significant step to deepen their collaboration in the development of high-end synthetic molecular enzymes.

This collaboration is based on a strong mutual consensus: Sanyou Bio possesses profound expertise in innovative biopharmaceutical discovery and development, while Yugong Bio holds core advantages in enzyme engineering and large-scale production. This powerful alliance will focus on the entire chain of enzyme product R&D, production, and application. By seamlessly integrating their respective superior resources, the partners aim to jointly overcome key technological bottlenecks in the biopharmaceutical field, committed to driving cost reduction, efficiency improvement, and technological innovation across the industry. This forward-looking strategic layout not only marks a new phase for the collaboration but also injects fresh momentum into the high-quality development of China’s biopharmaceutical industry.

Powerful Synergy: Complementary Strengths Form a Solid Foundation for Cooperation

Sanyou Bio is a biotechnology company focused on the discovery and development of innovative antibody drugs. Its internationally leading ultra-trillion-scale antibody library, combined with the dual drivers of “Efficient Screening + AI Analysis,” forms a powerful drug discovery engine. This platform enables rapid screening from massive libraries to precise candidates, significantly accelerating early-stage drug discovery and providing solid foundational innovation for R&D. This unique advantage injects a powerful “source of innovation” into early drug R&D, with its vast library capacity and exceptional screening efficiency already becoming an industry tool for accelerating drug discovery.

Yugong Bio is a national high-tech enterprise focusing on upstream molecular enzyme reagents for synthetic biology and their application solutions. The company possesses strong capabilities in enzyme molecular engineering and cell-free protein synthesis. Its enzyme products are renowned for high purity, high activity, and high stability, widely used in basic life science research, biopharmaceutical production, and bio-industrial fields, offering highly differentiated competitive advantages. Leveraging its deep expertise in enzyme engineering, Yugong Bio provides customers with stable, reliable, and cost-effective enzyme-related products and services.

Collaborative Win-Win: Strategic Cooperation Opens a New Future

This strategic collaboration is based on both parties’ profound understanding of industry trends and high recognition of each other’s technical capabilities. It aims to create core value through deep synergy across three levels:

1.  Resource Complementarity: Building End-to-End Capability from “Discovery” to “Delivery”: Sanyou Bio will utilize its trillion-scale molecular library and efficient screening platform to support Yugong Bio’s enzyme optimization and engineering for specific application scenarios. Yugong Bio will leverage its mature enzyme product R&D and large-scale production system to ensure the quality and stable supply of co-developed products. This integrated “Discovery + Optimization + Production” model will greatly accelerate the R&D industrialization process.

2.  Market Win-Win: Creating Cutting-Edge Products with Better Cost-Effectiveness: Through joint R&D and supply chain coordination, the partners aim to develop enzyme preparations and solutions with superior performance and lower cost. This will not only help reduce the R&D and production costs for both parties but also provide more cost-effective products for downstream customers, especially in fields like biopharmaceutical R&D and in vitro diagnostics, enhancing their market competitiveness.

3.  Industry Empowerment: Catalyzing Next-Generation Innovative Solutions: This collaboration represents a deep integration of cutting-edge molecular discovery capabilities and advanced enzyme engineering technology. It holds the potential to catalyze a batch of innovative enzyme products and solutions that lead the future, injecting new momentum into the entire biopharmaceutical industry.

Dr. David Lang, Founder and CEO of Sanyou Bio, stated: “The collaboration with Yugong Bio represents a deep coupling of cutting-edge molecular discovery capabilities and advanced enzyme engineering technology. We firmly believe that this strategic synergy will go beyond simple addition of advantages, transcend single, isolated R&D efforts, and create a seamlessly connected value loop, thereby accelerating scientific innovation and the commercial success of branded products.”

Dr. Henghao Xu, Founder and CEO of Yugong Bio, stated: “The strategic collaboration with Sanyou Bio is a significant step in Yugong Bio’s development journey. Sanyou’s exceptional capabilities in ultra-large capacity molecular libraries and screening will inject strong momentum into the foundational innovation of our enzyme products. We are confident that through close cooperation, we can bring more breakthrough products to the market, achieving win-win development.”

The strategic collaboration between Sanyou Bio and Yugong Bio is not merely a powerful alliance of complementary strengths but also a key milestone, marking a solid step forward in their journey to deepen industrial synergy and build core technological barriers.

About Yugong Bio

Jiangsu Yugong Biotechnology Co., Ltd. primarily addresses the “bottleneck” situation of upstream molecular enzyme raw materials in domestic synthetic biology and biopharmaceuticals, committed to providing more high-quality, economical, user-friendly enzyme products with independent intellectual property rights. The company headquarters is located in the China (Jiangsu) Pilot Free Trade Zone Lianyungang Area, constructed and managed with reference to GMP standards; its wholly-owned subsidiary Jiangsu Baisimei Biotechnology Co., Ltd., located in the Lianyungang National High-Tech Zone, is mainly responsible for R&D and research reagent production. The company adheres to independent R&D as its core and has established domestically leading cell-free protein synthesis and toxic protein recombinant expression technology platforms. It has been certified as a National High-Tech Enterprise and has obtained ISO13485 Quality Management System certification.

The company was the first in China to achieve large-scale production of the DNA “molecular scissors” – restriction endonucleases, breaking the complete monopoly of foreign companies for over 40 years. It currently ranks among the top three in the domestic restriction enzyme market share and has entered the supply chains of several leading domestic synthetic biology upstream enterprises. The company now possesses over 100 products across 11 series including restriction enzymes, cell-free protein synthesis, modification & cloning, PCR, isothermal amplification, reverse transcription, quantitative real-time PCR, and in vitro transcription, widely used in gene synthesis, molecular diagnostics, biomedical research, and other fields.

About Sanyou Bio

Sanyou Bio is a high-tech biopharmaceutical enterprise driven by its mission to “Enable Easy Innovation of Biologics for All” and powered by its ultra-trillion-scale molecular libraries and intelligent technology.

The company is dedicated to building a globally top-tier original innovation factory for new drugs. It centers on the AI-powered Super-Trillion Antibody Library (AI-STAL); relies on its integrated, intelligent, and internationally leading innovative biologics R&D platform combining in silico and wet-lab approaches; and promotes the R&D and industrialization of global innovative drugs through diversified business models.

The company is headquartered in Shanghai, China, and has established business centers in Asia, North America, Europe, and other regions, forming a global business network. It currently has over 20,000 square meters of R&D and GMP facilities in operation or under development.

The company has established sound cooperative relationships with over 2,000 pharmaceutical companies and biotechnology firms globally, has empowered more than 1,200 new drug R&D projects, and has completed over 50 cooperative R&D projects, more than 10 of which have advanced to the IND and clinical development stages.

The company has filed for over 130 invention patents, more than 30 of which have been granted. It has also obtained over 10 qualifications and system certifications including National High-Tech Enterprise, Shanghai Specialized, Refined, Distinctive, and New (SRDN) Enterprise, ISO9001, and ISO27001.

DETIKO Launches Black Friday Deals on Its Smart Bird Feeders

By
Advertorial Desk
-

NEW YORK, Nov. 11, 2025 /PRNewswire/ — This Black Friday season, DETIKO invites nature lovers and smart home enthusiasts to rediscover the outdoors through innovation. Until December 1, the brand’s new Smart Bird Feeder Series will be available on Amazon, with exclusive holiday discounts of up to 35%.


A Smarter Way to Connect with Nature

The DETIKO Smart Bird Feeder combines intelligent AI recognition with sustainable energy design, turning any backyard into an interactive wildlife hub. With a 2K HD wide-angle camera, real-time bird identification, and InstaVision app integration, users can watch, record, and share every feathered visitor. Each bird sighting is automatically recognized and logged, creating a personal “species diary” for the whole family. A key advantage is its 147° ultra-wide viewing angle, significantly broader than the typical 122°–130° range found in most feeders. This wider perspective greatly reduces blind spots and captures a larger feeding area, allowing users to observe and record every feathered visitor in full view.

The solar-powered system ensures effortless, year-round operation, while the weather-resistant body (IP65) keeps the device reliable through rain, snow, and sunshine. Whether for children learning about biodiversity or adults seeking peaceful moments amid daily life, DETIKO delivers the perfect blend of technology and tranquility.

Regular price: $149.99 → Black Friday: $96.99 (35% off)
Simple, durable, and intelligently designed, the ABS Edition features a red-and-green weatherproof housing with the same AI and solar-charging system, in a clean, modern shell ideal for any backyard.

Regular price: $169.99 → Black Friday: $118.99 (30% off)
Crafted from FSC-certified bamboo with a wing-shaped solar roof, the Bamboo Edition offers a natural aesthetic for eco-conscious users. Beneath its smooth finish lies the same advanced AI system, sustainably powered and beautifully integrated into the environment.

Both editions feature motion detection, night vision, real-time notifications, and multi-user family sharing through the InstaVision App.z

Perfect Gift for the Holiday Season

As the holiday season approaches, the DETIKO Smart Bird Feeder makes an ideal gift for families, educators, seniors, or anyone who loves nature. It transforms backyards into living classrooms, providing hours of peaceful observation and connection.

Both Black Friday deals are now live through the DETIKO Amazon Store, with an exclusive 5% off promo code (ACVA2OKD), valid through December 3.

Shop now and bring nature closer this season.

About DETIKO

DETIKO is an innovative technology brand dedicated to creating smart camera solutions that enhance everyday life. Focused on the intersection of people, nature, and technology, DETIKO develops intelligent imaging products for outdoor, home, pet, and automotive use. Powered by expertise in AI algorithms, IoT hardware, image processing, and secure U.S.-based cloud infrastructure, DETIKO designs products that combine reliable performance with intuitive user experiences. Through continuous innovation, the brand aims to make intelligent vision more accessible, helping users stay connected, secure, and inspired in their daily environments.

 

Wondershare Launches Filmora V15, Redefining Video Creation through Deep AI- Integrated Workflow

By
Advertorial Desk
-

VANCOUVER, BC, Nov. 11, 2025 /PRNewswire/ — Wondershare, a global leader in creative and productivity products and solutions, today announced the launch of Wondershare Filmora V15, marking a major step toward democratizing AI-powered video creation. Under the slogan “Edit as an Expert with Filmora AI”, the new version deeply integrates AI into every stage of the editing process, redefining how creators produce and refine content and ushering video production into a new era of intelligent creativity.


Wondershare today announced the launch of Wondershare Filmora V15, marking a major step toward democratizing AI-powered video creation.

Positioned as a next-generation all-in-one platform for professional video creation, Filmora V15 focuses on intelligent content generation and creative workflow management, seamlessly connecting every step from idea conception to final creation. The update also introduces a range of advanced tools, designed to simplify complex editing tasks and enhance creative control. Together, these upgrades make the workflow more intelligent, advanced editing more efficient, and professional features more intuitive, empowering creators of all levels to produce high-quality content with greater speed and ease in the AI era.

AI Integrated Workflow

Filmora V15 introduces a new level of AI integration, embedding intelligent capabilities throughout the creative pipeline. Instead of being standalone tools, Filmora’s AI features are seamlessly woven into the editing workflow — making AI a natural extension of the creative process. As the first all-in-one video creation software to offer an end-to-end professional experience — from AI content generation and extension to precise editing — Filmora V15 sets a new benchmark for intelligent video production.

In Filmora V15, AI functions as a continuous production flow that connects every stage of video creation — from ideation and generation to refinement and output. On the editing timeline, users can generate new scenes with AI Video Generation, remove distractions or adjust backgrounds with Smart Cutout, and extend footage using AI Extend. Combined with Dynamic Captions, Voice Clone, and Text-to-Speech, Filmora enables an uninterrupted workflow that turns talking-head videos into polished, share-ready content.

To enhance this connected workflow, Filmora V15 introduces new AI features and upgrades that deliver greater creative control and precision across all stages of editing:

  • AI Extend: Effortlessly continues clips directly on the timeline. Whether extending forward or backward, Filmora intelligently fills in missing footage with consistent visuals and smooth transitions, solving issues like insufficient clip length or abrupt cuts.
  • Smart Cutout: The upgraded AI better understands brush intent to accurately capture the desired subject, while enhanced edge-processing and smudging algorithms ensure cleaner, more precise results with fewer strokes and adjustments.
  • AI Object Remover: Now supports the Magic Box for quickly removing watermarks, subtitles, people, and other distractions while maintaining natural and seamless image quality.
  • AI Video Enhancer: Fully upgraded portrait enhancement preserves lighting and color fidelity, producing clearer, more natural, and stable results.

Smarter Editing for Complex Projects

Beyond AI, Filmora V15 introduces a series of updates that simplify complex editing while expanding creative possibilities:

  • Pen Tool: Freely draw paths or shapes, apply stroke effects, and bind motion to clips directly on the timeline — no third-party plugins required.
  • Animated Charts: Instantly transform imported data into animated bar or line charts, with customizable presets and dynamic storytelling effects.
  • Expanded Resource Library: Features a wider selection of Dynamic Captions, Text Animation, Video Animation, and cinematic filters, along with localized fonts and trending visual effects to meet diverse creative needs.

Simplified Professional Efficiency

Filmora V15 also brings professional-grade workflow upgrades designed for advanced users and production teams, evolving the software into a more comprehensive, intelligent editing ecosystem:

  • Dual-Timeline Editing: Manage multiple compound clips through tabs and switch between timelines seamlessly.
  • Subprojects: Import multiple project files as compound clips to simplify multi-project management and enable cross-project material reuse.
  • Source & Timeline Preview Editing: Preview source materials and live projects side-by-side for faster decision-making.
  • Multi-track Video: Provides expanded flexibility for layered video and audio editing.

Empowering Global Creators in the AI Era

“AI-generated content is reshaping the landscape of video creation,” said Christy, Vice President of Wondershare. “Filmora has evolved alongside creators for 15 years, continuously lowering the technical barriers to storytelling. Now, in the age of AI, Filmora is transforming from a video-editing tool into an intelligent creative partner — one that understands intent, automates complex processes, and seamlessly integrates AI into every stage of production, enabling creators to work faster, smarter, and with greater creative freedom than ever before.”

The global creator economy continues to accelerate, reaching an estimated $143 billion in 2024 and projected to grow tenfold by 2034 (Market.us). With Filmora V15, Wondershare offers creators a future-ready platform that unifies AI generation, intelligent editing, and professional control in one streamlined experience — making advanced video production accessible to everyone.

About Filmora:

Launched in 2015, Wondershare Filmora is designed with its user in mind, featuring smoother performance and an intuitive user interface, and has attracted a cumulative global user base of nearly 400 million across 150+ countries and regions. With advanced features boosting content generation and editing, over 2.9 million creative assets, commercially available music, 3D LUTs, effects, and pre-set templates, Filmora stands out as a leader in video editing software. Consistently introducing innovative tools, it enhances video creation and makes the process more efficient and accessible for all skill levels.

About Wondershare:

Wondershare is a globally recognized software company founded in 2003, known for its innovative solutions in creativity and productivity. Driven by the mission “Creativity Simplified”, Wondershare offers a range of tools, including Filmora, Virbo and SelfyzAI for video editing; PDFelement for document management; and EdrawMax, EdrawMind for diagramming. With over 2 billion cumulative active users across all products and a presence in over 200 countries and regions, Wondershare empowers the next generation of creators with intuitive software and trendy creative resources, continually expanding the possibilities of creativity worldwide.

True Global Ventures celebrates two major portfolio milestones in 72 hours, marking a defining moment in the U.S.

By
Advertorial Desk
-

Forge Global’s $660 million acquisition and Animoca Brands’ planned Nasdaq listing mark defining moments for the True Global Ventures Funds 4 and 5.

SINGAPORE, Nov. 11, 2025 /PRNewswire/ — True Global Ventures (TGV), the global venture capital firm investing in AI and Blockchain technology companies celebrates a historic week in the U.S.

Forge Global’s $660 million acquisition and Animoca Brands’ planned Nasdaq listing mark defining moments for the True Global Ventures Funds 4 and 5.
Forge Global’s $660 million acquisition and Animoca Brands’ planned Nasdaq listing mark defining moments for the True Global Ventures Funds 4 and 5.

Two of TGV’s flagship investments — Forge Global Holdings (NYSE: FRGE) and Animoca Brands Corporation Limited — have each achieved transformative milestones that highlight the fund’s long term commitment to backing visionary entrepreneurs shaping the future of finance and digital assets.

FORGE GLOBAL ACQUIRED BY CHARLES SCHWAB FOR $660 MILLION

Charles Schwab Corporation has agreed to acquire Forge Global for approximately US $660 million, valuing the company at about US $45 per share.

Forge Global has pioneered digital infrastructure that enables liquidity in private equity and venture capital, connecting investors, shareholders, and private companies in one of the world’s largest and fastest-growing secondaries ecosystems.

“Moments like this remind us why we invest for the long run,” said Dušan Stojanović, original founder of True Global Ventures, a visionary supporting extraordinary entrepreneurs. “Forge Global has redefined how liquidity is created and managed in private markets. Its acquisition by Charles Schwab reflects the accelerating convergence between traditional finance and the private-markets economy — a space where TGV has invested since inception. We believe that Forge Global will continue to innovate in areas like tokenisation of private company stock and funds!“

Kelly Rodrigues, CEO of Forge Global, added: “This partnership with Charles Schwab represents an inflection point for private markets. Forge was built to democratize access to private-company investments, and joining forces with one of the world’s most trusted financial institutions will dramatically accelerate that mission. We’re proud to have had long-term partners like TGV who believed in this vision from the start.”

ANIMOCA BRANDS PURSUING NASDAQ LISTING VIA CURRENC GROUP INC.

Animoca Brands has proposed a merger with Currenc Group Inc. (Nasdaq: CURR) through which Animoca’s shareholders would own approximately 95% of the combined entity. The merger is expected to complete in H2 2026 and result in a Nasdaq-listed company.

Animoca Brands is building the foundational layer of digital property rights. Its partnership with Currenc creates powerful potential synergies across cross-border payments, stablecoins, and tokenized digital assets — combining Web3 innovation with next-generation financial infrastructure.

Yat Siu, Co-Founder and Executive Chairman of Animoca Brands, commented: “A Nasdaq listing via Currenc represents a major step toward mainstream adoption of digital assets and tokenization. It enables us to bring the benefits of digital property rights — from gaming and education to finance and beyond — to an even broader audience.”

He continued: “Our collaboration with Currenc reflects shared DNA — both organizations are reinventing how value moves globally. Together, we aim to accelerate the transition toward open, interoperable digital economies. True Global Ventures has been a steadfast believer in this vision from the very beginning.”

Dušan Stojanović, commented: “Yat Siu is one of the most visionary entrepreneurs of our time. His leadership at Animoca Brands continues to shape the future of digital property rights. Our partnership spans over a decade, and seeing Animoca prepare for a Nasdaq listing is not only a testament to his vision, but to the power of persistence, innovation, and global collaboration. We are proud to have believed in this mission from its earliest stages.”

A DEFINING WEEK FOR TRUE GLOBAL VENTURES

These two milestones — one in private-markets liquidity, the other in digital-asset infrastructure — epitomize TGV’s investment philosophy: back visionary founders, accelerate scale in US and globally, bridge traditional finance with AI and Blockchain innovation.

A few months after being granted as a License Fund Management Company (LFMC) with a Capital Markets Services (CMS) license by the Monetary Authority of Singapore (MAS), True Global Ventures is now celebrating two major successes in the U.S, positioning itself among the best-performing venture capital funds globally.

ABOUT TRUE GLOBAL VENTURES
True Global Ventures (TGV) is a global venture capital firm investing in AI and Blockchain technology companies at the growth and late stages. TGV’s portfolio includes Animoca Brands, Forge Global, Ledger, The Sandbox, Prezent, Coding Giants, Obligo, COVU, Validation Cloud, SATO, Chromaway, Jus Mundi, BookitnGo, GCEX, Coinhouse…and many others. Almost all portfolio companies in the U.S. or entering the U.S. With presence across San Francisco, New York, Paris, London, Stockholm, Dubai, Singapore and Hong Kong, TGV backs visionary founders building the next generation of transformative technology ventures.

Learn more: https://www.tgv4plus.com/ 

Contact True Global Ventures: info@trueglobalventures.com 

Adama Builds With GoDaddy Airo

By
Advertorial Desk
-

ISLAMABAD, Pakistan, Nov. 11, 2025 /PRNewswire/ — For Adama Fall, football is more than a sport — it’s a platform. With roots in Senegal and a master’s degree in Cybersecurity underway at Arizona State University (ASU), Adama brings a global perspective and relentless drive to everything he does.

Through the ASU Student-Athlete Venture Studio, in collaboration with GoDaddy Empower, Adama is learning how to apply that same energy to his entrepreneurial journey. With GoDaddy Airo®, he’s exploring how AI-powered experiences can help him build a digital presence that reflects both his athletic career and his ambitions beyond the field.

This program is about more than name, image, and likeness (NIL) rights. It’s about giving athletes like Adama the ability to own their story and create a lasting legacy. Adama hopes to use technology and storytelling to empower other student athletes to build their legacy beyond the game.

Get started today at studentathlete.godaddy/Pakistan.

Watch Adama’s story here.

About GoDaddy
GoDaddy helps millions of entrepreneurs globally start and scale their businesses. People come to GoDaddy to name their idea, build a website and logo, sell their products and services, and accept payments. GoDaddy Airo®, the company’s AI-powered experience, makes growing a small business faster and easier by helping them to get their idea online in minutes, drive traffic and boost sales. GoDaddy’s expert guides are available 24/7 to provide assistance. To learn more about the company, visit www.GoDaddy.com.

GoDaddy Empower Spotlight Series
By partnering with diverse community organizations, schools, and education institutions, GoDaddy Empower helps emerging entrepreneurs of all ages and backgrounds build and grow their businesses online with free digital tools, training, and community. This article is part of the GoDaddy Empower spotlight series that shines a light on the individuals who make this unique initiative possible.

 

1...1,6931,6941,695...6,312Page 1,694 of 6,312